Home › Myositis › California › Los Angeles
Myositis clinical trials in Los Angeles, CA
3 studies for Myositis are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
RecruitingPhase 3
- 200 UCLA Medical Plaza, Los Angeles
- UCLA Clinical & Translational Research Center (CTRC), Los Angeles
- UCLA, Los Angeles
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
- Artiva Investigational Site Los Angeles, Los Angeles
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RecruitingPhase 1
- Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles
About Myositis
Myositis means inflammation of the muscles. Two specific types are polymyositis and dermatomyositis. Read about myositis symptoms and management.
More about Myositis on MedlinePlus
Myositis trials in other cities
- Durham, NC10 studies
- Boston, MA6 studies
- Chicago, IL6 studies
- New York City, NY6 studies
- Houston, TX5 studies
- Miami, FL4 studies
- Cedar Rapids, IA4 studies
- Orange, CA3 studies
- Baltimore, MD3 studies
- Pittsburgh, PA3 studies
- Washington, DC3 studies
- Jacksonville, FL3 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.